329,136 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 329,136 shares of the biopharmaceutical company's stock, valued at approximately $15,483,000. Cytokinetics accounts for approximately 1.9% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s investment portfolio, making the stock its 25th biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.28% of Cytokinetics as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Inspire Investing LLC raised its position in Cytokinetics by 7.8% in the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company's stock worth $400,000 after acquiring an additional 616 shares in the last quarter. Blue Trust Inc. increased its position in shares of Cytokinetics by 85.8% in the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 842 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Cytokinetics by 2.9% in the fourth quarter. Pacer Advisors Inc. now owns 24,843 shares of the biopharmaceutical company's stock valued at $1,169,000 after buying an additional 690 shares in the last quarter. R Squared Ltd purchased a new position in shares of Cytokinetics in the fourth quarter valued at $133,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Cytokinetics by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,023 shares of the biopharmaceutical company's stock valued at $1,177,000 after buying an additional 2,393 shares in the last quarter.

Insider Buying and Selling at Cytokinetics

In related news, CEO Robert I. Blum sold 16,970 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $43.44, for a total value of $737,176.80. Following the completion of the sale, the chief executive officer now owns 364,181 shares in the company, valued at approximately $15,820,022.64. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Andrew Callos sold 3,341 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total value of $144,565.07. Following the completion of the transaction, the executive vice president now directly owns 64,434 shares of the company's stock, valued at approximately $2,788,059.18. The trade was a 4.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,816 shares of company stock worth $3,850,385. 2.70% of the stock is currently owned by insiders.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $30.75 on Tuesday. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $61.40. The firm has a market capitalization of $3.67 billion, a PE ratio of -5.72 and a beta of 0.81. The business's 50 day moving average is $38.62 and its 200-day moving average is $45.04. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.05. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.77 million. Cytokinetics's quarterly revenue was up 89.1% compared to the same quarter last year. During the same quarter last year, the business earned ($1.33) EPS. Sell-side analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on CYTK. Cantor Fitzgerald upgraded Cytokinetics to a "strong-buy" rating in a research report on Tuesday, May 13th. Morgan Stanley set a $67.00 price objective on Cytokinetics in a research note on Friday, March 7th. JMP Securities reissued a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Thursday, April 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $72.00 target price on shares of Cytokinetics in a research report on Wednesday, May 14th. Finally, UBS Group reduced their price objective on shares of Cytokinetics from $47.00 to $41.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $74.44.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.